Contact Us

E-mail:Click here to contact us
We will send a reply within 24 hours on the next business day.
Response times may vary during U.S. holiday periods.
Phone: 1-866-4XOLAIR (1-866-496-5247) Monday–Friday, 8:30 AM–5:00 PM ET
Hours of operation may vary during U.S. holidays.
In case of medical emergency, please contact your physician immediately.
Mail: Customer Interaction Center
Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, New Jersey 07936-1080

Upon receipt of your letter, we will mail a reply to you within 2 business days. Please allow for U.S. Postal Service turnaround time. Response times may vary during U.S. holiday periods.

INDICATION
XOLAIR® (omalizumab) for subcutaneous use is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.

XOLAIR has been shown to decrease the incidence of asthma exacerbations in these patients.

Important Limitations of Use
XOLAIR is not indicated for treatment of other allergic conditions
XOLAIR is not indicated for the relief of acute bronchospasm or
status asthmaticus
XOLAIR is not indicated for use in pediatric patients less than
12 years of age

IMPORTANT SAFETY INFORMATION

WARNING: Anaphylaxis

Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, observe patients closely for an appropriate period of time after XOLAIR administration. Health care providers administering XOLAIR should be prepared to manage anaphylaxis that can be life-threatening. Inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care should symptoms occur (see Warnings and Precautions: Anaphylaxis).

XOLAIR should only be administered in a healthcare setting by healthcare providers prepared to manage anaphylaxis that can be life-threatening.
XOLAIR should not be administered to patients who have experienced a severe hypersensitivity reaction to XOLAIR or any ingredient of XOLAIR (see Warnings and Precautions). XOLAIR should be discontinued in patients who experience a severe hypersensitivity reaction.
Malignant neoplasms were observed in 20 of 4127 (0.5%) XOLAIR-treated patients compared with 5 of 2236 (0.2%) control patients in clinical studies of asthma and other allergic disorders.
XOLAIR has not been shown to alleviate asthma exacerbations acutely. Do not use XOLAIR to treat acute bronchospasm or status asthmaticus.
A constellation of signs and symptoms including arthritis/arthralgia, rash (urticaria or other forms), fever and lymphadenopathy similar to serum sickness have been reported in post-approval use of XOLAIR in some patients. Physicians should stop XOLAIR if a patient develops this constellation of signs and symptoms.
Patients should be given and instructed to read the accompanying Medication Guide before starting treatment and before each subsequent treatment.
Do not abruptly discontinue corticosteroid use upon initiation of XOLAIR therapy. Decrease corticosteroids gradually under the direct supervision of a physician.
In patients ≥12 years of age, the most commonly observed adverse reactions (>1% more frequent in XOLAIR-treated patients) from 4 placebo-controlled asthma studies were arthralgia (8%), pain (general) (7%), leg pain (4%), fatigue (3%), dizziness (3%), fracture (2%), arm pain (2%), pruritus (2%), dermatitis (2%), and earache (2%).
The adverse events most frequently resulting in clinical intervention (e.g. discontinuation of XOLAIR, or the need for concomitant medication to treat an adverse event), in either placebo-controlled or other controlled asthma studies, were injection site reaction (45%), viral infections (23%), upper respiratory tract infection (20%), sinusitis (16%), headache (15%), and pharyngitis (11%). These events were observed at similar rates in XOLAIR-treated patients and control patients.


Log In

Forgot your password?
Forgot which e-mail address we have on file?

LOG IN
triger

Forgot Which E-Mail
Address We Have On File?

Complete the fields below to display the e-mail address we have on file for your profile.
*INDICATES A REQUIRED FIELD

SUBMIT
triger

Forgot Which E-Mail
Address We Have On File?

Your e-mail address on file is:

 

CONTINUE LOG IN

E-Mail This Page

Share this information with colleagues.

To send this link to another healthcare professional, please fill out the form below.
*INDICATES A REQUIRED FIELD

SUBMIT
triger

Thank you for sharing with a colleague

 

CLOSE

DEACTIVATE YOUR ACCOUNT

Are you sure that you want to deactivate your account? You will no longer appear in the Physician Locator.

 

DEACTIVATECANCEL

TERMS AND CONDITIONS

Terms and Conditions Text

 

Close